Latest Director Appointments News

Zeotech Limited has made significant progress on its Toondoon Kaolin Project, securing critical environmental approvals, advancing mine planning, and preparing for an initial kaolin shipment amid rising contractor cost pressures.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Haranga Resources announces the resignation of Managing Director Peter Batten, with Chairman Michael Davy stepping in as interim executive to maintain momentum during the transition. The company continues its exploration activities uninterrupted while searching for a new leader.

ARC Funds Limited has been suspended from ASX trading due to a failure to maintain the minimum number of directors required by law, raising questions about its governance and future compliance.

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Skin Elements Limited reported a $4.01 million loss for the half-year ending December 2025, alongside a 41% revenue drop, while securing $2.5 million in fresh capital to advance its proprietary SE Formula biotechnology products.

Yowie Group Limited reported a steep 752% increase in its half-year loss to US$4.66 million, amid governance upheaval and impaired loans to its majority shareholder. The company faces ongoing legal and regulatory challenges while pursuing a turnaround.

Apiam Animal Health has officially become a wholly owned subsidiary of Adamantem Capital's entities following a scheme of arrangement, with shareholders receiving a special dividend and a mix of cash and shares. The company will soon be delisted from the ASX.

BSA Limited reported an 84% plunge in revenue for the half-year ending December 2025, driven by lost contracts and reduced volumes, yet managed a $6.3 million profit amid restructuring and cost controls. Significant board changes signal a strategic reset as the company navigates uncertain waters.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

SRG Global Limited posted a robust half-year result for December 2025, driven by strong segment growth and the acquisition of Total AMS Pty Ltd. The company also raised its interim dividend, signalling confidence in its outlook.

H&G High Conviction Limited has significantly reduced its half-year loss following asset divestment and is actively exploring strategic alternatives to enhance shareholder value amid looming ASX re-compliance requirements.